Long-term data on Dendreon’s Mylovenge™ vaccine presented at American Society of Hematology
Phase II studies indicate that Mylovenge causes regression or stabilization in over 30% of patients with multiple myeloma and amyloidosis, with some benefits lasting up to 18 months. The vaccine stimulates the immune system to recognize and destroy cancer cells.